Other Income/(expenses) , Net	12 Months Ended
Dec. 31, 2023
Other Income and Expenses [Abstract]
Other Income/(expenses) , Net	15. Other (expenses)/income, net In 2019, the Company acquired OncoMed in a business combination and subsequently renamed it Mereo BioPharma 5, Inc. At the time of the business combination, the Company’s intention was to sell or out-license Navi, rather than to invest in development of the asset in the course of the Company’s ordinary activities. In the approximately nine months between its acquisition and out-licensing of the worldwide rights of the asset in January 2020, Mereo BioPharma 5, Inc’s activities primarily involved out-licensing and winding-down the program. Due to the Company’s intention to sell or out-license Navi from the time of its acquisition and the lack of investment in development activities for the asset beyond wind-down costs, the Company concluded that entering into the license agreement was not in the course of its ordinary activities. Therefore, the licensee did not meet the definition of a “customer” as defined in ASC 606, as such, the license agreement was determined not to be within the scope of ASC 606. In February 2022, the Company received a milestone payment of $2.0 million under the Navi License Agreement. An associated payment was made to the former shareholders of Mereo BioPharma 5, Inc. under the CVR of $0.9 million, after deductions of costs, charges and expenditures, which resulted in other income, net of $1.1 million.

Other Income/(expenses) , Net

12 Months Ended

Dec. 31, 2023

Other Income and Expenses [Abstract]

15. Other (expenses)/income, net

In 2019, the Company acquired OncoMed in a business combination and subsequently renamed it Mereo BioPharma 5, Inc. At the time of the business combination, the Company’s intention was to sell or out-license Navi, rather than to invest in development of the asset in the course of the Company’s ordinary activities. In the approximately nine months between its acquisition and out-licensing of the worldwide rights of the asset in January 2020, Mereo BioPharma 5, Inc’s activities primarily involved out-licensing and winding-down the program.

Due to the Company’s intention to sell or out-license Navi from the time of its acquisition and the lack of investment in development activities for the asset beyond wind-down costs, the Company concluded that entering into the license agreement was not in the course of its ordinary activities. Therefore, the licensee did not meet the definition of a “customer” as defined in ASC 606, as such, the license agreement was determined not to be within the scope of ASC 606.

In February 2022, the Company received a milestone payment of $2.0 million under the Navi License Agreement. An associated payment was made to the former shareholders of Mereo BioPharma 5, Inc. under the CVR of $0.9 million, after deductions of costs, charges and expenditures, which resulted in other income, net of $1.1 million.